Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Calcipotriene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 13/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.98 |
| ▸ | PGR | P06401 | 2/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.98 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.98 |
| ▸ | HTR1A | P08908 | 1/20 | 0.98 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.66 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.63 |
| ▸ | GC | P02774 | 1/20 | 0.63 |
| ▸ | RXRA | P19793 | 1/20 | 0.63 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.63 |
| ▸ | CNR1 | P21554 | 1/20 | 0.63 |
| ▸ | HTR2C | P28335 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Calcipotriene SCHEMBL13044528 | 0.99 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL22364326 | 0.99 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL3278756 | 0.99 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL24066882 | 0.99 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL2132335 | 0.99 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL23339038 | 0.99 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL21849105 | 0.99 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL22364325 | 0.99 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL22364327 | 0.99 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL12311926 | 0.99 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 510 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119086793-A | Method for separating and measuring calcipotriol and impurity J thereof based on HPLC method | 重庆华邦胜凯制药有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-119055590-A | Anhydrous pharmaceutical composition for maintenance treatment of psoriasis | 利奥制药有限公司 | 2024-12-03 | — | — | CN | claimed |
| EP-4041186-B1 | AN ANHYDROUS PHARMACEUTICAL COMPOSITION FOR MAINTENANCE TREATMENT OF PSORIASIS | LEO PHARMA AS (DK) | 2024-05-22 | — | — | EP | claimed |
| EP-4041186-A1 | AN ANHYDROUS PHARMACEUTICAL COMPOSITION FOR MAINTENANCE TREATMENT OF PSORIASIS | Leo Pharma A/S (DK) | 2022-08-17 | — | — | EP | claimed |
| CN-114555055-A | Anhydrous pharmaceutical composition for the maintenance treatment of psoriasis | 利奥制药有限公司 | 2022-05-27 | — | — | CN | claimed |
| US-20210128588-A1 | PHARMACEUTICAL SPRAY COMPOSITION COMPRISING A VITAMIN D ANALOGUE AND CORTICOSTEROID | LEO PHARMA A/S | 2021-05-06 | — | — | US | claimed |
| WO-2021069496-A1 | AN ANHYDROUS PHARMACEUTICAL COMPOSITION FOR MAINTENANCE TREATMENT OF PSORIASIS | LEO PHARMA A/S (DK) | 2021-04-15 | — | — | WO | claimed |
| US-10716799-B2 | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid | LEO PHARMA A/S (DK) | 2020-07-21 | — | — | US | claimed |
| US-10688108-B2 | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid | LEO PHARMA A/S (DK) | 2020-06-23 | — | — | US | claimed |
| US-10682364-B2 | Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid | LEO PHARMA A/S (DK) | 2020-06-16 | — | — | US | claimed |
| WO-2005087719-A1 | STEREOSELECTIVE SYNTHESIS OF VITAMIN D ANALOGUES | LEO PHARMA A/S (DK) | 2005-09-22 | — | — | WO | claimed |
| US-20050118272-A1 | Micronized pharmaceutical or nutraceutical powder with immediate release | GALENIX INNOVATIONS (FR) | 2005-06-02 | — | — | US | claimed |
| US-20050042173-A1 | Micronized film-forming powder comprising an active substance | BESINS INTERNATIONAL BELGIQUE (BE) | 2005-02-24 | — | — | US | claimed |
| EP-1458356-A1 | MICRONIZED PHARMACEUTICAL OR NUTRACEUTICAL POWDER WITH IMMEDIATE RELEASE | Besins International Belgique (BE) | 2004-09-22 | — | — | EP | claimed |
| EP-1450772-A1 | MICRONIZED FILM-FORMING POWDER COMPRISING AN ACTIVE SUBSTANCE | Besins International Belgique (BE) | 2004-09-01 | — | — | EP | claimed |
| WO-2003055464-A1 | MICRONIZED PHARMACEUTICAL OR NUTRACEUTICAL POWDER WITH IMMEDIATE RELEASE | BESINS INTERNATIONAL BELGIQUE (BE) | 2003-07-10 | — | — | WO | claimed |
| US-20030124191-A1 | Use of an immediate-release powder in pharmaceutical and nutraceutical compositions | GALENIX INNOVATIONS (FR) | 2003-07-03 | — | — | US | claimed |
| WO-2003043612-A1 | MICRONIZED FILM-FORMING POWDER COMPRISING AN ACTIVE SUBSTANCE | BESINS INTERNATIONAL BELGIQUE (BE) | 2003-05-30 | — | — | WO | claimed |
| US-20030096012-A1 | Film-forming powder, compositions containing it, methods for their preparation and their uses | GALENIX INNOVATIONS (FR) | 2003-05-22 | — | — | US | claimed |
| US-5763426-A | DISSOLVING CALCIPOTRIOL IN ORGANIC SOLVENT AND ADDING WATER TO THE SOLUTION TO PRECIPITATE THE HYDRATE; STORAGE STABILITY; USEFUL FOR TREATMENT OF PSORIASIS | LEO PHARMACEUTICAL PRODUCTS LTD. (DE) | 1998-06-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10716799-B2 | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid | CYP24A1, CYP2R1, VDR | VDR 3/4885ADORA3 479/4885SLC6A2 1627/4885 |
| US-20210128588-A1 | PHARMACEUTICAL SPRAY COMPOSITION COMPRISING A VITAMIN D ANALOGUE AND CORTICOSTEROID | CYP24A1, CYP2R1, VDR | VDR 3/4885ADORA3 480/4885SLC6A2 1938/4885 |
| US-10682364-B2 | Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid | CYP24A1, CYP2R1, VDR | VDR 3/4885ADORA3 506/4885SLC6A2 1758/4885 |
| US-10688108-B2 | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid | CYP24A1, CYP2R1, VDR | VDR 3/4885ADORA3 479/4885SLC6A2 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.